These results provide valuable insight into the synergistic mechanism between SNX-7081 and 2-FaraA that may provide an alternative treatment for CLL patients with p53 mutations, for whom therapeutic options are currently limited. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.